AgomAb Therapeutics garners $74m Series B

Drug developer AgomAb Therapeutics has secured $74 million in Series B financing.

Drug developer AgomAb Therapeutics has secured $74 million in Series B financing. Redmile Group led the round with participation from other backers that included Cormorant Asset Management, Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax and V-Bio Ventures.

Source: Press Release